MedTrace Logo

A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment

NCT01689350 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2014-09-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the genotype-based personal prescription of cyclophosphamide with the traditional prescription.

Conditions

Interventions

GENETIC

Genotype Detection

To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Huang Min, PhD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-12-31
Completion
2014-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01689350 on ClinicalTrials.gov